Mikhail Blagosklonny is a revered New York-based professor of oncology who has made significant contributions in cancer treatment. He currently works at the Buffalo-based Rosewell Park Cancer Institute and has done a lot of research about cancer therapies. Blagosklonny also works at Oncotarget where he is the editor-in-chief and has published a lot of research work that focuses on aging. He is recognized for promoting the use of a cancer drug that is called Rapamycin. He believes that the cure can significantly increase the lives of cancer patients. The professor has made great accomplishments during his career life. Rapamycin is a drug that was formed to prevent rejections during organ transplants. It is also known as Sirolimus. Other uses of the drug include curing a rare lung disease, hemolytic-uremic syndrome, lymphangioleiomyomatosis (LAM), facial angiofibromas, tuberous sclerosis complex (TSC), and coating coronary stents. Its trade name in the pharmaceuticals world is Rapamune and is recognized as a cancer drug. Rapamycin was first created in 1972 from bacteria samples that were discovered on Eastern Island. It was first used as an anti-fungal agent before scientists found out that it had antiproliferative and immunosuppressive properties.
Blagosklonny has been working to ensure that cancer patients get the best cures since he believes that human life is valuable. The main areas that he has been dealing with in the medical research world are aging and cancer treatment. He is focused on linking the two fields since cancer mostly affects old people who are past a certain age. Mikhail is determined to conduct research that will be beneficial to the oncology world. His success as a professor in the field has made him be an inspiration to his peers and students.The scientist attended First Pavlov State Medical University of St. Peterburg where he completed his master’s degree in internal medicine before enrolling for his Ph.D. in cardiology and experimental medicine at the institution. He was hired by the Valhalla-based New York Medical College in 2002 and later become a senior scientist at the Ordway Research Institute.
Mikhail worked at the organization until 2009 when he got a chance to serve Roswell Park Cancer Institute as a professor of oncology. The professor has developed an interest in researching about targeted cancer therapies that the prevent health human body cells from being damaged. He has also been studying the mechanism of aging and the development of anti-aging drugs. Mikhail has come up with a hypothesis that tries to explain the role of TOR signaling in cancer and aging. He has advised medical practitioners to use rapamycin in lengthening their cancer patients’ lives.he professor has also been involved in editorial undertakings. He acts as editor-in-chief of oncotarget, cell cycle, and aging. Mikhail is also a cancer biology and therapy associate editor and has been part of the cell death and differentiation editorial board. He has written hundreds of research papers, book chapters, and articles about cancer treatment. His work at the Rosewell Park Cancer Institute is greatly acknowledged.